Results that matter,
When they matter

WHY MYCARE PSYCHIATRY?

MyCare quickly provides objective information, and when used in combination with other clinical information, may help you make better-informed treatment decisions and enhance shared decision making between you and your patient.

MyCare provides greater clarity on the causes of threatment failure (i.e. adherence, drug resistance, drug-drug interactions and drug metabolism) and may help distinguish medication non response from lack of adherence. This information may help you establish the right medication at the right dose more quickly than you would based solely on patient self-report.

Where it works today:

Emergency Departments

CMHCs with CLIA Lab

In-Patient / Out-Patient with access to central lab

MYCARE UNLOCKS POTENTIAL

Improved Patient Care

Increased Drug Efficacy

Limit Adverse Effects

Prevents Drug-to-Drug Interaction

Improved Medical Adherence

Improved Economic Efficiencies

WHO SHOULD TAKE THE TEST

While caregivers want monthly testing, it is also beneficial in treatment of patients:

  • With questionable adherence
  • With medications that aren’t working
  • Unwelcome side effects from current medications
  • On multiple medications
  • With medications which require blood levels
  • Who require switching medication

WHERE IT WORKS

Emergency Departments

CMHCs with CLIA Lab

In-Patient / Out-Patient

CLINICAL STUDIES

The literature is full of publications on the problem of adherence with patients taking oral antipsychotics. It is equally full of publications acknowledging that lack of insight into patient treatment failures is a problem. It is also clear that blood level testing can be an aid in the treatment of patients on antipsychotics.

``Medication adherence in schizophrenia``

ABSTRACT

Medication adherence in schizophrenia: Factors influencing adherence and consequences of non-adherence – a systematic literature review

Kyoko Higashi, Goran Medic, Kavi J. Littlewood, Teresa Diez, Ola Granström, Marc De Hert, Ther Adv Psychopharmacol. 2013 Aug; 3(4): 200–218.

A systematic review of factors that influence adherence and the consequences of nonadherence to the patient, healthcare system and society, in patients with schizophrenia. Particular attention was given to the effect of nonadherence on hospitalization rates, as a key driver of increased costs of care. A qualitative systematic literature review was conducted using a broad search strategy using disease and adherence terms.

``Predictors and clinical consequences of non-adherence``

ABSTRACT

Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia

Eli Lilly and Company, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK. Novick_diego@lilly.com

To assess baseline predictors and consequences of antipsychotic adherence during the long-term treatment of schizophrenia outpatients, data were taken from the 3-year, prospective, observational, European Schizophrenia Outpatients Health Outcomes (SOHO) study, in which outpatients starting or changing antipsychotics were assessed every 6 months. Physician-rated adherence was dichotomized as adherence/non-adherence. Regression models tested for predictors of adherence during follow-up, and associations between adherence and outcome measures. Of the 6731 patients analysed, 71.2% were adherent and 28.8% were non-adherent over 3 years.

``Therapeutic drug monitoring of atypical antipsychotic drugs``

ABSTRACT

Therapeutic drug monitoring of atypical antipsychotic drugs

MILAN GRUNDMANN IVANA KACIROVA1, ROMANA URINOVSKA
Department of Clinical Pharmacology Faculty of Medicine University of Ostrava, Ostrava, Czech Republic, Department of Clinical Pharmacology Department of Laboratory Diagnostics University Hospital Ostrava, Ostrava Czech Republic

Schizophrenia is a severe psychiatric disorder often associated with cognitive impairment and affective, mainly depressive, symptoms. Antipsychotic medication is the primary intervention for stabilization of acute psychotic episodes and prevention of recurrences and relapses in patients with schizophrenia. Typical antipsychotics, the older class of antipsychotic agents, are currently used much less frequently than newer atypical antipsychotics. Therapeutic drug monitoring (TDM) of antipsychotic drugs is the specific method of clinical pharmacology, which involves measurement of drug serum concentrations followed by interpretation and good cooperation with the clinician. TDM is a powerful tool that allows tailor-made treatment for the specific needs of individual patients.

``Recidivism for individuals with psychotic disorders``

ABSTRACT

Recidivism for individuals with psychotic disorders was twice as high in the US compared with 9 other countries

For individuals with serious mental illness who have committed major crimes, past studies have shown that if they do not continue treatment when they are placed in the community, their re-arrest rate is 40% to 60% within 5 years. However, if such individuals maintain treatment upon community reentry, their re-arrest rate can be reduced to 10% or lower.

TALK TO YOUR PATIENT

Your patients will likely have questions about MyCare Psychiatry test. Below are possible responses to commonly asked questions:

“How often do I have to take the test?”

MyCare is generally not needed at every appointment, and we can decide together how often to perform the test. MyCare tends to be most useful when we think it may be appropriate to adjust your medication. For example, when symptoms or side effects begin to show.

“What will you do with the results?”

Similar to measuring your cholesterol or blood sugar, we can use MyCare to help you meet your treatment goals and guide decisions about your medication. Just like all of your other medical information, MyCare results are private and protected.

“Who will explain the results to me?”

Your intake nurse may take your blood sample and your treating health care provider will explain the results to you.

“Is this a test to see if I’m taking street drugs?”

MyCare can only measures the amount of antipsychotic medication in your body. MyCare isn’t able to measure any other drugs, including street drugs.

“Will it hurt?”

The test requires a simple blood draw. It may feel like a quick pinch at first, but there is usually very little pain afterwards.

GET STARTED BY ORDERING A FREE INFORMATION KIT

Start typing and press Enter to search